A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
Studying ALK-negative anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- Jun Zhu
- Principal Investigator
- Jun Zhu, MDPeking University Cancer Hospital & Institute
- Intervention
- crizotinib(drug)
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2015 – 2017
Study locations (1)
- Weiping Liu, Beijing, Beijing Municipality, China
Collaborators
Peking University First Hospital · Peking University People's Hospital · Peking University Third Hospital · Peking Union Medical College Hospital · Beijing Hospital · Chinese PLA General Hospital · First Hospitals affiliated to the China PLA General Hospital · Air Force General Hospital of the PLA · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Anhui Provincial Hospital · Zhejiang University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02487316 on ClinicalTrials.govOther trials for ALK-negative anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07300514Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaFudan University
- RECRUITINGPHASE2NCT07356245Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaJonathan Brammer
- RECRUITINGPHASE1NCT06176690Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasBaylor College of Medicine
- RECRUITINGPHASE1NCT07001384A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)Memorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT07013565Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLNew York Medical College
- RECRUITINGPHASE2NCT05996185Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaYale University
- RECRUITINGPHASE1NCT06508463Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT04925609Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid TumorsPrincess Maxima Center for Pediatric Oncology
See all trials for ALK-negative anaplastic large cell lymphoma →